Literature DB >> 20501612

Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis.

Saori Matsuba-Kitamura1, Tomohiro Yoshimoto, Koubun Yasuda, Shizue Futatsugi-Yumikura, Yuuko Taki, Taichiro Muto, Tomohiro Ikeda, Osamu Mimura, Kenji Nakanishi.   

Abstract

IL-33, a member of the IL-1 family of cytokines, is the ligand for ST2 (IL-33Ralpha chain). IL-33 has the capacity to induce T(h)2 cytokine production from T(h)2 cells, mast cells and basophils, indicating that IL-33 has the potential to induce T(h)2 cytokine-mediated allergic inflammation of the eye. Thus, we tested the pathological role of IL-33 in allergic conjunctivitis (AC). As reported elsewhere, animals immunized with ragweed pollen (RW)/alum and boosted with RW/PBS developed AC promptly (within 15 min) and conjunctival eosinophilic inflammation after a delay (within 24 h) in response to eye drop challenge with RW. Furthermore, RW-immunized mice, when topically challenged with both RW and IL-33, developed more striking eosinophilia in their conjunctiva without exacerbation of the clinical AC score. This in vivo IL-33 treatment significantly increased the capacity of T cells in the cervical lymph nodes of RW-immunized mice to produce IL-4, IL-5 and IL-13 upon challenge with anti-CD3 and anti-CD28 antibodies in vitro. Furthermore, the infiltrating cells were largely eosinophils and a small proportion of CD4(+) T cells, both of which express ST2. We also found that even splenic eosinophils express ST2 and show increased expression in response to IL-5, granulocyte-macrophage colony-stimulating factor (GM-CSF) or IL-33. Eosinophils, stimulated with IL-5 and/or GM-CSF, are responsive to IL-33, which induces production of IL-4 and chemokines. Finally, we showed that conjunctival tissues constitutively express biologically active IL-33, suggesting that IL-33 might play a crucial role in the induction and augmentation of AC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501612     DOI: 10.1093/intimm/dxq035

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  43 in total

Review 1.  Interleukin-33 biology with potential insights into human diseases.

Authors:  Gaby Palmer; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2011-04-26       Impact factor: 20.543

Review 2.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

Review 3.  Interleukin 33: a switch-hitting cytokine.

Authors:  Daniel O Villarreal; David B Weiner
Journal:  Curr Opin Immunol       Date:  2014-04-22       Impact factor: 7.486

4.  Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation.

Authors:  Luca Pastorelli; Carlo De Salvo; Marissa A Cominelli; Maurizio Vecchi; Theresa T Pizarro
Journal:  Therap Adv Gastroenterol       Date:  2011-09       Impact factor: 4.409

5.  Granulocytes in Ocular HSV-1 Infection: Opposing Roles of Mast Cells and Neutrophils.

Authors:  Derek J Royer; Min Zheng; Christopher D Conrady; Daniel J J Carr
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-06       Impact factor: 4.799

6.  Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3⁺ regulatory T-cell responses in mice.

Authors:  Lihua Duan; Jie Chen; Hongwei Zhang; Heng Yang; Ping Zhu; Ali Xiong; Quansong Xia; Fang Zheng; Zheng Tan; Feili Gong; Min Fang
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

7.  Potential autocrine regulation of interleukin-33/ST2 signaling of dendritic cells in allergic inflammation.

Authors:  Z Su; J Lin; F Lu; X Zhang; L Zhang; N B Gandhi; C S de Paiva; S C Pflugfelder; D-Q Li
Journal:  Mucosal Immunol       Date:  2013-01-09       Impact factor: 7.313

Review 8.  Implications for Interleukin-33 in solid organ transplantation.

Authors:  Quan Liu; Hēth R Turnquist
Journal:  Cytokine       Date:  2013-03-27       Impact factor: 3.861

9.  IL-33 markedly activates murine eosinophils by an NF-κB-dependent mechanism differentially dependent upon an IL-4-driven autoinflammatory loop.

Authors:  Carine Bouffi; Mark Rochman; Christopher B Zust; Emily M Stucke; Andrey Kartashov; Patricia C Fulkerson; Artem Barski; Marc E Rothenberg
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

10.  Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.

Authors:  Geethani Bandara; Michael A Beaven; Ana Olivera; Alasdair M Gilfillan; Dean D Metcalfe
Journal:  Eur J Immunol       Date:  2015-09-09       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.